Cancer: a short review of current publications of interest:
references for using Vitamin D, Quercetin, Ginseng, Milk thistle, selenium
and progesterone for treating ovarian cancer.
and the other platinum chemotherapy drugs are the most common choice in
treating ovarian cancer, thus my particular focus on what will increase
effect of this drug.
D : Vitamin D (1.25 dihydroxycholecalcifero) and its analogue
1,25-dihydroxy-16-ene-23-yne-cholecalciferol (Ro23-7553) (pronounce
that one!) have significant antitumor effect. Pretreatment with the
vitamin D analogue, Ro23-7553 markedly enhanced cisplatin's tumor cell
kill, even at low doses of cisplatin as compared to cisplatin treatment
: Quercetin has an antiproliferative effect on ovarian cancer
cells, inhibiting their growth. 
Other bioflavinoids, hesperidin and rutin have no effect. Quercetin
increases cisplatin's effect: “The combination of the two drugs resulted
in a synergistic antiproliferative activity.” 
extracts given orally to mice with ovarian cancer significantly
increased the effect of cisplatin at killing the tumor cells. Ginseng
allowed lowering the dose of cisplatin to a point where side effects
were not detectable while achieving similar tumor killing activity.
thistle (silybin) extracts inhibit growth of ovarian cancer
cells and prevent angiogenesis: 
When given with cisplatin they increase the drug's effectiveness
at killing the tumor cells: “Administration of both drugs resulted in
a protentiation of the antitumor activity….” 
A similar effect is seen when given with doxorubicin (Adriamycin).
: Many MDs advise their patients not to take any antioxidant
vitamins or herbs during chemotherapy. There is little published evidence
to support this advice. On the other hand, there is considerable evidence
that these substances are beneficial. A recent case study of two women
with ovarian cancer taking a number of different antioxidant vitamins
(oral vitamin C, vitamin E, beta-carotene, coenzyme Q-10 and a multivitamin/mineral
complex. lus one patient added parenteral ascorbic acid, 60 grams twice
per week) reporting significant benefit: “…..Antioxidants, when added
adjunctively, to first-line chemotherapy, may improve the efficacy of
chemotherapy and may prove to be safe. …….. Because of the positive
results found in these two patients, a randomized controlled trial is
now underway at the University of Kansas Medical Center evaluating safety
and efficacy of antioxidants when added to chemotherapy in newly diagnosed
ovarian cancer.” 
K-3 and Vitamin C : In a 1/100 combination these vitamins cause
ovarian cancer cells to self destruct. 
Studies with other cancer types, suggest this vitamin combination
may make cancer cells more sensitive to chemotherapy treatment.
: Administering selenium with cisplatin did not increase the
anti tumor effect of cisplatin but did decrease the side effects; “The
co-administration of selenium together with cisplatin……. did not affect
the anti-tumour activity of CDDP (cisplatin) but it did cause a decrease
of parameters of host toxicity including lethality, increasing the 50%
lethal dose (LD50) from 9.3 mg kg-1 to 17.5 mg kg-1. The parameters
of host toxicity which were altered by selenium co-administration were
nephrotoxicity, myeloid suppression and weight loss.” 
--- Progesterone: Although epidemiological evidence suggests
some link between ovarian cancer and hormone replacement therapy, current
publications suggest that estrogen may be the promoting agent and that
progesterone may be protective: “pregnancy-equivalent levels progesterone
are highly effective as apoptosis inducers for OSE and OCa (ovarian
cancer) cells. ” 
Cancer Res. 1997 Sep 1;57(17):3759-64. Potentiation of cisplatin
antitumor activity using a vitamin D analogue in a murine squamous cell
carcinoma model system.Light BW, Yu WD, McElwain MC, Russell DM, Trump
DL, Johnson CS.
Br J Cancer. 1990 Dec;62(6):942-6.
effect of quercetin on OVCA 433 cells and presence of type II oestrogen
binding sites in primary ovarian tumours and cultured cells. Scambia G,
Ranelletti FO, Panici PB, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina
G, Rumi C, Larocca LM, Mancuso S.
Anticancer Drugs. 1990 Oct;1(1):45-8. Synergistic antiproliferative
activity of quercetin and cisplatin on ovarian cancer cell growth.
G, Ranelletti FO, Benedetti Panici P, Bonanno G, De Vincenzo R, Piantelli
M, Mancuso S.
Jpn J Cancer Res. 1998 Jul;89(7):733-40
effects of ginsenoside Rh2 on tumor growth in nude mice bearing human
ovarian cancer cells.
H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, Kudoh K, Nagata I, Shinomiya
Eur J Cancer. 2003 Nov;39(16):2403-10.
activity of the silybin-phosphatidylcholine complex, IdB 1016, against
human ovarian cancer.
Life Sci. 2002 Feb 8;70(12):1447-59. Silybin and its bioavailable
phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity
S, Gallo D, Apollonio P, Ferlini C, Distefano M, Morazzoni P, Riva A,
Bombardelli E, Mancuso S, Scambia G.
Eur J Cancer. 1996 May;32A(5):877-82 Antiproliferative effect of
silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.Scambia
G, De Vincenzo R, Ranelletti FO, Panici PB, Ferrandina G, D'Agostino G,
Fattorossi A, Bombardelli E, Mancuso S.
J Am Coll Nutr. 2003 Apr;22(2):118-23 The use of antioxidants with
first-line chemotherapy in two cases of ovarian cancer. Drisko JA, Chapman
J, Hunter VJ.
Anticancer Res. 2003 Jul-Aug;23(4):3279-87.
in vitro antitumor activity of vitamins C and K3 against ovarian carcinoma.
Gruenigen VE, Jamison JM, Gilloteaux J, Lorimer HE, Summers M, Pollard
RR, Gwin CA, Summers JL.
Br J Cancer. 1988 Jul;58(1):38-41 The effects of co-administration
of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour
K, Tsukada Y, Dohzono H, Koike K, Terashima Y.
Reprod Biol Endocrinol. 2003 Oct 7;1(1):73.
Progesterone and Epithelial Ovarian Cancer.